02/20/2026
Kenya has received an initial shipment of 21,000 starter doses of the long-acting injectable Lenacapavir for HIV pre-exposure prophylaxis (PrEP).
Lenacapavir is not a vaccine or a cure for HIV. It is a preventive treatment that significantly reduces the risk of acquiring HIV in people who are HIV-negative.
Administered just twice a year, the medication is expected to be offered at an estimated annual cost of approximately KES 7,800 per patient—a dramatic reduction from its previous price of about USD 42,000 per year.
This progress is encouraging. Still, we believe this medication must be accessible, available, and affordable to everyone who needs it—because prevention should never be a privilege.